The AI breakthrough in healthcare is still years away

Despite all the rage among startups, Silicon Valley and health IT professionals about how artificial intelligence (AI) could revolutionize healthcare, the technology just isn’t there yet, according to a report in VentureBeat.

What’s holding AI back for now isn’t money, considering tech giants such as IBM and Apple are investing billions in the technology. Applications still need to achieve artificial narrow intelligence, or ANI, or outperforming humans in fairly complex scenarios.

“To date, the sweet spot in healthcare AI has been pairing algorithms with structured exercises in reading patient data and medical images to train machines to detect abnormalities. This training is called ‘deep learning,'” healthcare consultant Brian Scogland said. “In the same way, algorithms are being used to sift through vast amounts of medical literature to inform treatment decisions where it would be too onerous a task to have a human read through the same journals.”

There are still technological, psychological and regulatory barriers to overcome, however, which makes predicting when the big breakthrough will occur difficult.

“I have no doubt that sophisticated learning and AI algorithms will find a place in health care over the coming years,” said Andy Schuetz, a senior data scientist at Sutter Health. “I don’t know if it’s two years or 10—but it’s coming.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.